Not only do we demonstrate the imperative role of FBXW7 in control of EMT and NSCLC cell invasion, but also its pivotal responsibility to guarantee effectiveness of gefitinib via inhibiting mTOR/p70S6K pathway in EGFR‐mutated NSCLC. This evidence concerns the gene RPS6KB1 and non-small cell lung carcinoma.